1.1.1.141: 15-hydroxyprostaglandin dehydrogenase (NAD+)

This is an abbreviated version, for detailed information about 15-hydroxyprostaglandin dehydrogenase (NAD+), go to the full flat file.

Reaction

(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
+
NAD+
=
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate
+
NADH
+
H+

Synonyms

11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD+ 15-oxidoreductase, 15-hydroxy prostaglandin dehydrogenase, 15-hydroxy-prostaglandin-dehydrogenase, 15-hydroxyprostaglandin dehydrogenase, 15-hydroxyprostaglandin-dehydrogenase, 15-hydroxyprostanoic dehydrogenase, 15-OH-PGDH, 15-PGDH, 15-prostaglandin dehydrogenase, dehydrogenase, 15-hydroxyprostaglandin, HPGD, NAD+ dependent 15-hydroxyprostaglandin dehydrogenase, NAD+ dependent PGDH, NAD+-15-hydroxy prostanoate oxidoreductase, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (type I), NAD+-dependent 15-PGDH, NAD+-linked 15-hydroxyprostaglandin dehydrogenase, NAD-dependent 15-hydroxyprostaglandin dehydrogenase, NAD-specific 15-hydroxyprostaglandin dehydrogenase, nicotinamide adenine dinucleotide-dependent 15-hydroxyprostaglandin dehydrogenase, PGDH, prostaglandin dehydrogenase

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.141 15-hydroxyprostaglandin dehydrogenase (NAD+)

Inhibitors

Inhibitors on EC 1.1.1.141 - 15-hydroxyprostaglandin dehydrogenase (NAD+)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
-
-
(1-phenyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
-
-
(1-tert-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
-
-
(3,3-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
-
-
(3,5-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
-
-
(4-([(4-chlorophenyl)sulfanyl]methyl)phenyl)(4-methylpiperidin-1-yl)methanone
-
-
(4-bromopiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
-
-
(4-[(2-bromophenoxy)methyl]phenyl)(piperidin-1-yl)methanone
-
-
(5Z)-5-[3-bromo-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(3-cyclohexylpropoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(4-cyclohexylbutoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(cyclohexylmethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(cyclohexyloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(9Z,12E)-13-hydroxyoctadeca-9,12-dienoic acid
-
0.01 mM, 45% inhibition
(piperidin-1-yl)[1-[3-(propan-2-yl)phenyl]-1H-benzimidazol-5-yl]methanone
-
-
(piperidin-1-yl)[1-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
-
-
(piperidin-1-yl)[1-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
-
-
1,2-naphthoquinone
-
0.0002 mM, time dependent inactivation, 1 mM glutathione or 40% glycerol protect from inactivation; inactivation, glutathione protects
12-O-tetradecanoylphorbol-13-acetate
-
10 nM, rapid loss of activity in eryrthroleukemia cells during 40 min, inhibition can be prevented by staurosporin indicating that protein kinase C is involved; induces the synthesis of 15-PGDH but inhibits the enzyme activity a protein kinase C mediated mechanism
13-cis-Prostaglandin F2alpha
-
; 0.124 mM, 50% inhibition
13-hydroxyperoxyoctadecadienoic acid
-
0.001 mM to 0.01 mM, 50% inhibition with 0.003 mM, uncompetitive inhibition vs. NAD+, noncompetitive vs. prostaglandin E2
15-deoxy-DELTA12,14-prostaglandin J2
-
0.024 mM, 50% inhibition
15-epi-prostaglandin E1
-
-
15-Epiprostaglandin E1
-
0.17 mM, 50% inhibition
15-ketoprostaglandin E1
-
-
15-ketoprostaglandin E2
-
-
2,4,6-Trinitrobenzenesulfonic acid
-
-
2-([(6-bromo-4H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl)benzonitrile
-
-
2-azido NAD+
-
photoaffinity analog of NAD+, 0.115 mM, complete inactivation
2-hydroxy-5-(3,5-dimethoxycarbonyl-benzoyl)-benzene acetic acid
2-methyl-1,4-naphthoquinone
-
0.02 mM, time dependent inactivation
2-[[(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl]benzonitrile
-
-
3,3',5-triiodothyronine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8,9,10-hexahydro[1,2,4]triazolo[4,3-a]azocine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9,10,11-hexahydro-5H-[1,2,4]triazolo[4,3-a]azonine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole
-
-
3-[1-(3,4-dichlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[1-(3-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[1-(4-methoxyphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[1-(4-tert-butylphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[2,5-dimethyl-1-(4-methylphenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[2,5-dimethyl-1-(4-nitrophenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[2,5-dimethyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[2,5-dimethyl-1-[4-(naphthalen-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[2,5-dimethyl-1-[4-(pyridin-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[2,5-dimethyl-1-[4-(pyridin-3-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[2,5-dimethyl-1-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[2,5-dimethyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
-
-
4,5-benzo[a]pyrenequinone
-
0.0002 mM, time dependent inactivation
4-((2,5-dioxopyrrolidin-3-ylidene)methyl)phenylthiophene-2-carboxylate
-
-
-
4-chloromercuriphenylsulfonic acid
-
-
4-methoxybenzyl-2,4-thiazolidinedione
-
-
4-methoxybenzylidene-2,4-thiazolidinedione
-
-
4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
-
-
5-(2-chloro-3-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(2-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(2-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(2-chloro-4-(2-cyclohexylethoxy)benzylidene)-thiazolidine-2,4-dione
-
-
-
5-(2-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(2-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
-
-
-
5-(2-chloro-4-phenbutoxybenzylidene)thiazolidine-2,4-dione
-
-
-
5-(2-chloro-4-phenethoxybenzylidene)thiazolidine-2,4-dione
-
-
-
5-(2-chloro-4-phenpropoxybenzylidene)thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-((4-(prop-1-en-2-yl)cyclohexyl)methoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-(4-methyl-1,3-thiazolidin-5-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-(5-ethylpyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-(5-nitrofuran-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-cyclopropylpropyl)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(2-thiomorpholine 1,1-dioxideethoxy)benzylidene)-2,4-thiazolidinedione
-
-
-
5-(3-chloro-4-(3-(2-nitroethenyl)phenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(3-nitrophenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(3-phenylpropoxy)benzylidene)thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(4-phenylbutoxy)benzylidene)thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(cyclobutylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-(cyclopentylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(3-chloro-4-phenylethoxybenzylidene)thiazolidine-2,4-dione
-
-
-
5-(4-((4-methylcyclohexyl)methoxy)benzylidene) thiazolidine-2,4-dione
-
-
5-(4-(1,3-benzodioxol-5-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(4-(2-(thiophen-3-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(4-(2-cyclopentylethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(4-(4-(chloromethyl)benzyloxy)benzylidene) thiazolidine-2,4-dione
-
-
5-(4-(benzyloxy)-2-chlorobenzylidene)thiazolidine-2,4-dione
-
-
-
5-(4-(benzyloxy)-3-chlorobenzylidene)thiazolidine-2,4-dione
-
-
-
5-(4-(bicyclo[2.2.1]hept-2-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
-
-
-
5-(4-(cyclopentylmethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-[4-((1-methyl)-cyclohexylmethoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-((1-methyl)-cyclohexylmethoxy)benzyl]-2,4-thiazolidenedione
-
trivial name ciglitazone
5-[4-(benzoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylbutoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylethoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylmethoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexyloxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylpropoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[[4-(ethoxycarbonyl)phenyl]azo]-2-hydroxy-benzeneacetic acid
-
CAY-10397, specific 15-PGDH inhibitor
5-[[4-(ethoxycarbonyl)phenyl]azo]2-hydroxy-benzene acetic acid
CAY-10397
7,8-benzo[a]pyrenequinone
-
0.0002 mM, time dependent inactivation, 40% glycerol protects from inactivation; inactivation, glutathione protects
-
7-Oxa-13-prostynoic acid
-
; 0.0475 mM, 50% inhibition
7-oxa-prostanoic acid
-
-
7-Oxoprostanoic acid
-
-
7-Thia-13-prostynoic acid
-
; 0.0068 mM, 50% inhibition
7-thia-prostanoic acid
-
-
Acetylsalicylate
-
-
acrolein
-
irreversible inhibition
adenosine-5'-diphosphoribose
-
-
arachidonic acid
Berberine
-
0.023 mM, 50% inhibition
Biochanin A
-
0.031 mM, 50% inhibition
CAY 10397
-
specific inhibitor, completely reverses the stimulating effect of ibuprofen on cell proliferation in TT cells
chalcone
-
0.016 mM, 50% inhibition
chrysin
-
0.021 mM, 50% inhibition
ciglitazone
CT-8
-
-
-
Cu2+
-
0.05 mM to 0.5 mM, 50% inhibition with 0.1 mM, uncompetitive vs. NAD+, non-competitive vs. prostaglandin E2
curcumin
-
0.01 mM, 50% inhibition
diethyldicarbonate
-
-
DuP 697
-
0.022 mM, 50% inhibition
-
ent-13-dehydro-15-epi-prostaglandin F2alpha
-
-
Ent-13-dehydro-15-epiprostaglandin F3alpha
-
0.055 mM, 50% inhibition
ent-13-dehydroprostaglandin E2
-
; 0.0068 mM, 50% inhibition
epi-7-thia-prostaglandin F2alpha
-
-
epi-7-thiaprostaglandin F2alpha
-
0.0052 mM, 50% inhibition
epigallocatechin gallate
-
0.012 mM, 50% inhibition
Ethacrynic acid
ethanol
ethyl 4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzoate
-
-
Flufenamic acid
-
0.041 mM, 50% inhibition
flurbiprofen
-
0.062 mM, 50% inhibition
genistein
-
-
glycerol
-
slight inhibition
hexadecanoic acid
-
0.01 mM
ICI 81008
-
-
indomethacin
ketorolac
-
0.028 mM, 50% inhibition
-
linoleic acid
-
0.01 mM, 30% inhibition
Meclofenamic acid
-
0.073 mM, 50% inhibition
Mefenamic acid
-
0.076 mM, 50% inhibition
mixture of endogenous fatty acids
-
mixture contains palmitic acid, stearic acid linoleic acid and oleic acid, competitive vs. prostaglandine E2
-
MK 886
-
0.037 mM, 50% inhibition
N,N-diethyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
-
-
N-(2-phenylethyl)-indomethacin amide
-
0.098 mM, 50% inhibition
-
N-(3-pyridyl)-indomethacin amide
-
0.1 mM, 50% inhibition
-
N-butyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
-
-
N-Chlorosuccinimide
-
-
N-cyclopentyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
-
-
N-ethylmaleimide
NADPH
nat-13-dehydroprostaglandin E2
-
-
nat-13-dehydroprostaglandin F3alpha
-
-
Nat-13-thiaprostaglandin F2alpha
-
0.0088 mM, 50% inhibition
-
nat-7-thia-prostaglandin F2alpha
-
-
nat-l3-dehydroprostaglandin F2alpha
-
-
niflumic acid
-
0.058 mM, 50% inhibition
nimesulide
-
0.051 mM, 50% inhibition
NS 398
-
0.064 mM, 50% inhibition
-
octadecanoic acid
-
0.01 mM
p-Chloromercuriphenylsulfonic acid
-
-
papaverine
PD 98059
-
an ERK kinase inhibitor
Phenylglyoxal
-
-
Prostaglandin B1
prostaglandin E1
-
-
prostaglandin E2
prostaglandin F2alpha
-
-
Prostanoic acid
pyridoxal 5'-phosphate
-
-
resveratrol
-
0.054 mM, 50% inhibition
rosiglitazone
sulfaphasalazine
-
sulindac
-
0.041 mM, 50% inhibition
sulindac sulfide
-
0.018 mM, 50% inhibition
sulindac sulfone
-
0.038 mM, 50% inhibition
tetradecanoic acid
-
0.01 mM
Tetraiodothyroacetic acid
-
-
Tetranitromethane
-
-
thyroxine
troglitazone
Zn2+
-
0.05 mM to 0.5 mM, 50% inhibition with 0.15 mM, uncompetitive vs. NAD+, non-competitive vs. prostaglandin E2
[1-(2-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(3-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(3-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-methylpiperidin-1-yl)methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-phenylpiperidin-1-yl)methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](4-methylpiperazin-1-yl)methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](morpholin-4-yl)methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](pyrrolidin-1-yl)methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(propan-2-yl)piperidin-1-yl]methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(trifluoromethyl)piperidin-1-yl]methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][4-(trifluoromethyl)piperidin-1-yl]methanone
-
-
[1-(3-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(4-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(4-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(4-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(4-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[4-(4-methoxyphenyl)piperazin-1-yl](4-[(phenylsulfanyl)methyl]phenyl)methanone
-
-
additional information
-